Aldeyra announces positive Phase 2 data for ADX-629 in atopic dermatitis; advancing ADX-246

Aldeyra Therapeutics, Inc.

Phase 2 trial of ADX-629 in 8 mild-to-moderate atopic dermatitis patients showed statistically significant improvement from baseline in EASI (p=0.0006) and IGA (p<0.0001).
Three patients (38%) achieved EASI-75; one patient (13%) had complete clearance of affected body surface area; two patients (25%) reported elimination of itching.
Only two mild treatment-related adverse events reported; no serious adverse events or discontinuations. All eight patients completed the trial.
Company plans to initiate a randomized placebo-controlled Phase 1/2 trial of ADX-246 in H1 2024, with topline results expected in H2 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.